The FDA has approved the first treatment for severe multiple sclerosis. The decision came Tuesday after clinical trials showed positive results when treating patients with both severe MS and the more common form of the disease in regression. Treating both severe and mild forms of the disease, scientists believe that this may enable treatments to begin earlier and prevent more severe reactions in the future. The drug, Ocrevas, will be sold by Genentech and is listed at 25% less in cost than the nearest competing therapy. Read the full article here.
